Initial clinical outcomes of proton beam radiotherapy for hepatocellular carcinoma
- Author:
Jeong Il YU
1
;
Gyu Sang YOO
;
Sungkoo CHO
;
Sang Hoon JUNG
;
Youngyih HAN
;
Seyjoon PARK
;
Boram LEE
;
Wonseok KANG
;
Dong Hyun SINN
;
Yong Han PAIK
;
Geum Youn GWAK
;
Moon Seok CHOI
;
Joon Hyeok LEE
;
Kwang Cheol KOH
;
Seung Woon PAIK
;
Hee Chul PARK
Author Information
- Publication Type:Original Article
- Keywords: Hepatocellular carcinoma; Proton; Radiotherapy; Response; Toxicity
- MeSH: Carcinoma, Hepatocellular; Follow-Up Studies; Humans; Liver; Proton Therapy; Protons; Radiotherapy; Response Evaluation Criteria in Solid Tumors
- From:Radiation Oncology Journal 2018;36(1):25-34
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: This study aimed to evaluate the initial outcomes of proton beam therapy (PBT) for hepatocellular carcinoma (HCC) in terms of tumor response and safety. MATERIALS AND METHODS: HCC patients who were not indicated for standard curative local modalities and who were treated with PBT at Samsung Medical Center from January 2016 to February 2017 were enrolled. Toxicity was scored using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Tumor response was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). RESULTS: A total of 101 HCC patients treated with PBT were included. Patients were treated with an equivalent dose of 62–92 GyE10. Liver function status was not significantly affected after PBT. Greater than 80% of patients had Child-Pugh class A and albumin-bilirubin (ALBI) grade 1 up to 3-months after PBT. Of 78 patients followed for three months after PBT, infield complete and partial responses were achieved in 54 (69.2%) and 14 (17.9%) patients, respectively. CONCLUSION: PBT treatment of HCC patients showed a favorable infield complete response rate of 69.2% with acceptable acute toxicity. An additional follow-up study of these patients will be conducted.
